Glp-1 weight loss denied as experimental or investigational by Cigna?

Cigna's commercial coverage policy IP0206 targets liraglutide (Saxenda, generic), Wegovy, and Zepbound for chronic weight management and requires prior authorization. For adult initial therapy, the patient must have a BMI ≥ 30 kg/m² (obesity), or a BMI exceeding 30 or a comorbid condition, such as diabetes or hypertension, with a BMI over 27 ; recognized weight-related comorbidities include hypertension, Type 2 diabetes, dyslipidemia (high cholesterol), obstructive sleep apnea, or cardiovascular disease . Pediatric criteria require BMI ≥ 95th percentile for age and sex . Initial approval durations differ by product: approve for 4 months for Saxenda initial therapy , approve for 7 months of Wegovy initial therapy , and approve for 8 months of Zepbound initial therapy , with 1-year reauthorization contingent on continued therapy and demonstrated weight-loss response. For continuation, response to pharmacologic therapy should be assessed after 3 months on a therapeutic dose; if treatment has not resulted in ≥ 5% weight loss, longer-term efficacy will not likely be sufficient and a change is recommended; individuals with weight reduction ≥ 5% should continue with their current treatment . Additional MACE-reduction coverage exists for Wegovy in adults with established cardiovascular disease with overweight or obesity (e.g., prior MI, stroke, or symptomatic peripheral arterial disease), and Wegovy for MASH/NASH must be prescribed by or in consultation with a physician who specializes in the condition being treated ; Wegovy is not indicated in patients with cirrhotic (F4) MASH . Combined use with another GLP-1 or GLP-1/GIP agonist is not approved, and quantity limits restrict claims to one GLP-1 agonist at a time.

- For BMI/comorbidity denials: cite FDA labeling and AACE/Obesity Society guidelines supporting pharmacotherapy at BMI ≥ 30 or ≥ 27 with comorbidities; submit chart documentation of measured BMI and ICD-10-coded comorbidity (HTN, T2DM E11, OSA G47.33, dyslipidemia E78). - For lifestyle-modification denials: provide documented participation in a structured reduced-calorie diet, physical activity, and behavioral counseling, consistent with the policy's own framework that treatment is to address complications and diseases, not solely to reduce BMI, and the choice of pharmacotherapy is based on obesity-related comorbidities ; reference the STEP and SURMOUNT trial protocols which paired drug therapy with lifestyle intervention. - For inadequate-response denials at reauthorization: provide weighed clinic measurements showing ≥ 5% loss; note the policy itself acknowledges patients who achieve ≥ 15% weight loss (the average observed with Wegovy and Zepbound) achieve a response that predictably prevents or improves a wide range of complications — supported by STEP 1 (Wilding NEJM 2021) and SURMOUNT-1 (Jastreboff NEJM 2022). - For cardiovascular indication denials on Wegovy: cite the SELECT trial (Lincoff NEJM 2023) showing 20% MACE reduction; per policy, established cardiovascular disease with overweight or obesity is approvable with documentation of prior MI, stroke, or symptomatic PAD. - For OSA-related denials on Zepbound: cite SURMOUNT-OSA results referenced in the policy itself — in both trials, Zepbound was superior to placebo for the primary endpoint; in Trial 1, the change in AHI at Week 52 with Zepbound was superior to placebo (-25.3 events/hour vs. -5.3 events/hour) ; align with ATS 2018 OSA weight-management guideline recommending anti-obesity pharmacotherapy in BMI ≥ 27 patients. - For MASH/NASH denials on Wegovy: provide specialist (hepatology/GI) attestation and documentation of stage F2 or F3 fibrosis confirmed by liver biopsy within 3 years, vibration-controlled elastography (VCTE), or MRE ; cite ESSENCE trial results. - For "not medically necessary" denials: reference ADA Standards of Care 2024 and AACE 2023 endorsing GLP-1 RAs and GLP-1/GIP agonists for chronic weight management with cardiometabolic comorbidities, and the AHA 2021 Scientific Statement on obesity and CVD risk.

## Why Cigna May Label GLP-1 Weight-Loss Treatment "Experimental"

This denial category — also described as "investigational" or "not medically accepted" — means Cigna's medical policy has determined that the specific use being requested does not yet meet the plan's evidentiary standard for coverage. For GLP-1 agonists in the context of weight management, this most commonly occurs when the drug is being used for an indication or a patient population that Cigna's current coverage policy considers to be outside established clinical evidence — for example, in a patient whose profile differs from the population studied in the FDA approval, or when a newer indication is being applied before the plan has updated its coverage determination.

## Why This Denial Is Appealable

FDA approval itself is strong evidence that a use is not experimental. If your GLP-1 prescription is for an FDA-approved indication, the plan's "experimental" label may reflect an outdated or overly narrow coverage policy. Published guidelines from recognized obesity medicine and endocrinology professional societies, along with the FDA-approved prescribing information, are the primary tools for rebutting this denial. An independent external reviewer applies clinical standards, not just the plan's internal policy, and can overturn an experimental designation that is inconsistent with mainstream clinical evidence.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal with the deadline on your denial notice. Request that Cigna's clinical reviewer identify specifically which aspect of the use it considers experimental, so you can address it directly.
• External review (ACA §2719): This is a particularly powerful tool for experimental denials, because the external reviewer — an independent, accredited organization — is required to apply objective clinical evidence standards, not just the plan's proprietary coverage policy. Standard review closes within 45 days; expedited within 72 hours for urgent cases.
• Request the clinical policy: Cigna is required to provide the specific coverage policy and the evidence standards it used. Request this in writing as part of your appeal.

## Documentation to Gather

• FDA prescribing information: The current FDA-approved label documenting the approved indication and the patient population for the specific GLP-1 agent prescribed — this directly addresses an "experimental" or "not medically accepted" designation.
• Diagnosis and eligibility documentation: Records confirming that the patient's diagnosis, clinical profile, and prior treatment history place them squarely within the FDA-approved indication.
• Prescriber medical-necessity letter: A letter from your physician citing the FDA approval, referencing the applicable professional society guideline (e.g., the Obesity Medicine Association or the American Association of Clinical Endocrinologists) generically, and explaining why this use represents accepted medical practice.
• Peer-reviewed literature (optional): Your prescriber may choose to attach a recent review article from a recognized medical journal as supplementary support — without relying on specific statistics from it.

## Criteria-Mapping Structure

Obtain Cigna's specific experimental/investigational coverage policy for GLP-1 agents in weight management. Then address each stated evidentiary gap:

| Cigna's Stated Experimental Basis | Rebuttal Evidence | |---|---| | Not FDA-approved for this use | [FDA label — indication and patient population] | | Outside accepted medical practice | [Professional society guideline reference via prescriber letter] | | Patient profile outside studied population | [Diagnosis records confirming approved indication applies] |

A concise, document-driven appeal that directly answers the experimental designation is far more effective than a general clinical argument.